2021 Year in Review and Trends in Healthcare Financing and M&A for 2022 Online

Dec 6, 2021 · ,
Virtual meeting hosted by Zoom Video Conferencing Following registration, a confirmation email with a link to join the webinar will be sent

Program Description

Join us for our Annual Financing and M&A Outlook conference. Some life science sectors have seen significant disruption during the pandemic, others have experienced an upsurge in demand. However, life sciences companies will continue to thrive thanks to market demand and demographics.

Gabriele Brambilla, Chief Executive Officer, Alira Health, will be the keynote speaker. He will be joined by a panel of multidisciplinary experts from Investment banking, Private Equity Funds, Corporate Venture, and Venture Capital. Hear from these industry leaders on the latest trends in investments and transactions from 2021 and predictions for 2022.

Keynote Speaker

Gabriele Brambilla, Chief Executive Officer, Alira Health

Alira Health is an international firm providing integrated strategy, execution, and innovation services for healthcare and life science companies. Gabriele is passionate about healthcare innovation. In addition to his appointment as Alira Health CEO in 2014, he serves on the Board of Directors for leading-edge start-ups EnlightenVue, WoundForce, Firefly, and Computational Life.

Program Panelist

Jeffrey Barlow, President, Canaccord Genuity LLC (US)

Jeff joined the firm in February 2007 and successfully expanded the firm’s Life Sciences practice before becoming head of US Investment Banking in 2011. He has extensive experience advising clients in all aspects of financings, mergers, and acquisitions and has completed more than 150 transactions during his career.

Omar Khalil, Partner, Santé Ventures

Santé invests in a diverse portfolio of innovative companies across biology, medicine, and information technology. Omar Khalil rejoined Santé in 2020, concentrates on biotechnology and medical devices, and manages the Boston Office.

David Neustaedter, Vice President, Venture Capital, Medtronic

As vice president of venture capital at Medtronic, Dave works with Medtronic’s leadership team and operating units to complete relevant minority investments in high-performing companies. Dave has led 20 investments since 2010 and has served as a Director or Observer on around 25 Boards.

Bruce C. Robertson, Ph.D., Managing Director, H.I.G. Capital

H.I.G. BioHealth Partners is the healthcare-focused affiliate of H.I.G. Capital, which collectively manages $45 billion in private capital. H.I.G. BioHealth Partners invests in a broad range of product-based healthcare companies, including pharmaceuticals, biotechnology, medical devices, and diagnostics.

Join this timely program to hear about how these leaders are adapting to the current market challenges.

Who should attend?

C-level executives, board members, investors, and other senior leaders who want a better understanding of how to make important decisions at strategic inflection points for their company in 2022.

Speaker Bios

Jeffrey Barlow, President, Canaccord Genuity LLC (US)

Jeffrey G. Barlow, CFA, was appointed President of Canaccord Genuity LLC (US) in October 2015. Mr. Barlow joined the firm in February 2007 and successfully expanded the firm’s Life Sciences practice before becoming head of US Investment Banking in 2011. He has extensive experience advising clients in all aspects of financings, mergers, and acquisitions and has completed more than 150 transactions during his career.

Prior to joining Canaccord Genuity, Mr. Barlow was a Managing Director and the Head of Healthcare Investment Banking at First Albany Corporation, where he was responsible for establishing and building the firm’s healthcare practice.

Mr. Barlow began his career at J.P. Morgan. Mr. Barlow earned the Chartered Financial Analyst (CFA) designation and is a frequent speaker on industry topics. He received his B.A. from the University of New Hampshire and MBA with Beta Gamma Sigma distinction from the Leonard N. Stern School of Business at New York University.

Gabriele Brambilla, Chief Executive Officer, Alira Health

Gabriele Brambilla was appointed Alira Health’s Chief Executive Officer in 2014 and has led U.S. operations since 2010. In his role as CEO, Gabriele continues to develop Alira Health’s corporate and product lifecycle capabilities and help our clients to accelerate their innovation.

In 2018 he co-founded the MetroWest Life Sciences Network, a regional collaboration of healthcare and life science-based organizations, municipalities, and economic and business development organizations located in Boston’s MetroWest region, which is home to Alira Health’s headquarters. His work as the Chairman of this thriving network is helping to bring greater collaboration, innovation, and entrepreneurship to this critical life sciences ecosystem. Gabriele is also on the Board of Directors of EnlightenVue, WoundForce, Firefly, and Computational Life. In 2019, Gabriele was named Business Leader of the Year by the MetroWest Chamber of Commerce.

Gabriele began his career in pharmaceuticals, working for an Italian firm based in Shanghai. He has also gained strong expertise in the medical device areas, specifically with contract manufacturing, fluid management, medical imaging, and infection control.

Gabriele received his BA in Political Science from the University of Pavia, a master’s degree in International Affairs from the I.S.P.I., and an MBA from Post Graduate SDA Bocconi in Milan, Italy.

David Neustaedter, Vice President, Venture Capital, Medtronic

As vice president of venture capital at Medtronic, Dave works with Medtronic’s leadership team and operating units to complete relevant minority investments in high performing companies pursuing important new therapies, subsequently partnering with portfolio companies to help them succeed. Dave has led 20 investments since 2010 and has served as a Director or Observer on around 25 Boards including IDEV (acquired by Abbott), superDimension (acquired by Covidien), TVA (acquired by Becton Dickinson), PQ Bypass (acquired by Endologix), Entellus (Nasdaq: ENTL, acquired by Stryker), Inspire (NYSE: INSP), and NeuroPace (Nasdaq: NPCE).

Prior to Medtronic, Dave worked as a healthcare-focused strategy consultant and contributed to strategy, business development, and venture capital at Stryker and Covidien. A Canadian farm boy, Dave earned his B.Sc. (Honours) from the University of Calgary, a Ph.D. in molecular biology from the University of British Columbia, and then an MBA from Yale University.

Bruce C. Robertson, Ph.D., Managing Director, H.I.G. Capital

Bruce Robertson is a Managing Director at H.I.G. Capital, a $45 billion global private equity firm, where he is the co-head of H.I.G.’s dedicated healthcare fund, H.I.G. BioHealth Partners. Bruce currently serves on the boards of Apollo Endosurgery, CardioFocus, Exagen, Zerigo Health, Augmedics, and Iconic Therapeutics.

Bruce has been active in the life sciences sector for more than 30 years. Prior to joining H.I.G., Bruce was a partner in two prior private equity firms. Prior to his private equity career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN's partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.

Bruce holds Bachelors degrees in Chemical Engineering and Mathematics from the University of Pennsylvania, a Ph.D. in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.

Omar Khalil, Partner, Santé Ventures

Omar Khalil rejoined Santé in 2020, concentrates on biotechnology and medical devices and manages the Boston Office. Prior to that, he held senior leadership roles with Baxter International, Baxalta (now part of Takeda) and Kaléo. He has managed and led businesses ranging from early clinical development, commercial launch and scaling to more than $3 Billion in annual sales. He spent four years at Santé as a Principal, investing Funds I and II. Earlier in his career, he worked at McKinsey & Company in the healthcare practice, where he served leading medical device and pharmaceutical companies.

He received his MSE and BSE in Biomedical Engineering summa cum laude from the University of Michigan with a concentration in Tissue Engineering.

SPONSORSHIP KINDLY PROVIDED BY


		2021 Year in Review and Trends in Healthcare Financing and M&A for 2022 image

		2021 Year in Review and Trends in Healthcare Financing and M&A for 2022 image

		2021 Year in Review and Trends in Healthcare Financing and M&A for 2022 image

		2021 Year in Review and Trends in Healthcare Financing and M&A for 2022 image

		2021 Year in Review and Trends in Healthcare Financing and M&A for 2022 image

		2021 Year in Review and Trends in Healthcare Financing and M&A for 2022 image

		2021 Year in Review and Trends in Healthcare Financing and M&A for 2022 image

		2021 Year in Review and Trends in Healthcare Financing and M&A for 2022 image
Event organizers

Are you organizing 2021 Year in Review and Trends in Healthcare Financing and M&A for 2022?

Claim the event and start manage its content.

I am the organizer
Online Event
Online Event

A place to meet the most active, international community members

Social
Rating

based on 0 reviews